FDA clears tiratricol for MCT8 deficiency, lowering dangerous T3 and outlining dosing, lab testing, and pharmacy access.
|Videos|March 20, 2014
Specialty Medication Distribution
Suzanne Tschida, PharmD, BCPS, vice president of specialty benefit and outcomes strategy at OptumRx, talks about how specialty medications are better suited for distribution through a specialty pharmacy over a retail location.
Advertisement
Suzanne Tschida, PharmD, BCPS, vice president of specialty benefit and outcomes strategy at OptumRx, talks about how specialty medications are better suited for distribution through a specialty pharmacy over a retail location.
This video was shot at the 2013 Academy of Managed Care Pharmacy in San Antonio, Texas.
Advertisement
Related to this article
Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.
The once-daily tablet is the third approved treatment for fibrodysplasia ossificans progressiva (FOP), with CYP3A4 and metformin interaction guidance.
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Tavapadon, First D1/D5 Agonist for Parkinson Disease
2
Engineered Stem Cell Therapy Reverses New-Onset T1D in Mice by Reprogramming T Cells
3
CagriSema Tops Tirzepatide 5 mg for Weight Loss in REIMAGINE 5
4
CKD Prevalence Unmoved Despite Billions in Virtual Care
5